down arrow

ADC Therapeutics SA

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CH0499880968
USD
3.54
-0.41 (-10.38%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

3.493.90

52 Week

1.054.80
Valuation
Technical
Day's Volume

CASH

699.56 k

Shareholding (Mar 2025)

FII

8.21%

Held by 25 FIIs

DII

72.71%

Held by 16 DIIs

Promoter

10.13%

How big is ADC Therapeutics SA?

22-Jun-2025

As of Jun 18, ADC Therapeutics SA has a market capitalization of 343.74 million and reported net sales of 75.81 million, with a net profit of -149.84 million over the last four quarters. The balance sheet shows shareholder's funds of -202.64 million and total assets of 321.98 million.

As of Jun 18, ADC Therapeutics SA has a market capitalization of 343.74 million, categorized as a Micro Cap.<BR><BR>As of Jun 18, the company reported net sales of 75.81 million for the latest four quarters. During the same period, the consolidated net profit was -149.84 million.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of -202.64 million and total assets of 321.98 million.

Read More

What does ADC Therapeutics SA do?

22-Jun-2025

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology company specializing in antibody drug conjugates for cancer treatment. As of March 2025, it reported net sales of $23 million and a net loss of $39 million, with a market cap of $343.74 million.

Overview: <BR>ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company in the Pharmaceuticals & Biotechnology industry, focusing on antibody drug conjugates for cancer treatment.<BR><BR>Financial Snapshot: <BR>Net Sales: 23 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -39 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 343.74 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.07 <BR>Return on Equity: 68.70% <BR>Price to Book: -1.44 <BR><BR>Contact Details: <BR>Address: Biopole, route de la Corniche 3B, EPALINGES None: 1066 <BR>Tel: ['41 21 6530200'] <BR>Website: https://adctherapeutics.com/

Read More

Who are in the management team of ADC Therapeutics SA?

22-Jun-2025

As of March 2022, the management team of ADC Therapeutics SA includes Chairman Ron Squarer, CEO Chris Martin, Vice Chairman and CFO Michael Forer, and Board Members Dr. Peter Corr and Dr. Peter Hug. This team is responsible for the company's strategic direction and operations.

As of March 2022, the management team of ADC Therapeutics SA includes the following individuals:<BR><BR>- Mr. Ron Squarer, who serves as the Chairman of the Board of Directors.<BR>- Dr. Chris Martin, the Chief Executive Officer and a Member of the Board of Directors.<BR>- Mr. Michael Forer, who is the Vice Chairman of the Board of Directors, as well as the Executive Vice President and Chief Financial Officer.<BR>- Dr. Peter Corr, a Member of the Board of Directors.<BR>- Dr. Peter Hug, also a Member of the Board of Directors. <BR><BR>This leadership team plays a crucial role in guiding the company's strategic direction and operations.

Read More

Is ADC Therapeutics SA overvalued or undervalued?

20-Sep-2025

As of August 3, 2021, ADC Therapeutics SA is considered risky and overvalued due to significant financial distress, reflected in its negative key ratios and poor long-term performance, despite a strong year-to-date stock return.

As of 3 August 2021, the valuation grade for ADC Therapeutics SA moved from does not qualify to risky. The company is currently overvalued based on its financial metrics. Key ratios include a Price to Book Value of -1.62, an EV to EBIT of -5.11, and an EV to EBITDA of -5.24, all indicating significant financial distress. In comparison to peers, ADC Therapeutics has a less favorable EV to EBITDA ratio than G1 Therapeutics, Inc. at -9.6487 and Alpha Teknova, Inc. at -14.9899, which further underscores its challenging position.<BR><BR>Despite a strong year-to-date stock return of 70.35% compared to the S&P 500's 12.22%, the long-term performance is concerning, with a 5-year return of -92.55% versus the S&P 500's 96.61%. This stark contrast suggests that while there may be short-term gains, the overall valuation and financial health of ADC Therapeutics remain precarious.

Read More

Is ADC Therapeutics SA technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, ADC Therapeutics SA has a mildly bullish trend, supported by bullish MACD and Bollinger Bands, but faces caution from some bearish indicators, while it has outperformed the S&P 500 recently despite significant long-term underperformance.

As of 8 September 2025, the technical trend for ADC Therapeutics SA has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on the weekly timeframe and a bullish signal from Bollinger Bands on both weekly and monthly timeframes. However, the KST and Dow Theory indicators are mildly bearish on the monthly timeframe, indicating some caution. <BR><BR>In terms of performance, ADC Therapeutics has outperformed the S&P 500 over the past week and month, with returns of 1.80% and 4.63% respectively, while the S&P 500 returned 1.05% and 2.33%. However, the longer-term returns show significant underperformance over 3 years and 5 years compared to the S&P 500.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -12.16
2

Flat results in Jun 25

3

Risky - Negative EBITDA

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 405 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.93

stock-summary
Return on Equity

84.56%

stock-summary
Price to Book

-2.03

Revenue and Profits:
Net Sales:
19 Million
(Quarterly Results - Jun 2025)
Net Profit:
-57 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
4.12%
0%
4.12%
6 Months
5.99%
0%
5.99%
1 Year
71.01%
0%
71.01%
2 Years
218.92%
0%
218.92%
3 Years
-2.21%
0%
-2.21%
4 Years
-83.5%
0%
-83.5%
5 Years
-90.13%
0%
-90.13%

ADC Therapeutics SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
ADC Therapeutics SA Hits New 52-Week High of $4.80

ADC Therapeutics SA Hits New 52-Week High of $4.80

ADC Therapeutics SA achieved a new 52-week high of USD 4.80 on October 30, 2025, reflecting a strong performance over the past year. With a market capitalization of USD 405 million, the company operates in the Pharmaceuticals & Biotechnology sector, despite being loss-making and lacking dividends.

Read More
ADC Therapeutics SA Hits New 52-Week High of $4.67

ADC Therapeutics SA Hits New 52-Week High of $4.67

ADC Therapeutics SA has achieved a new 52-week high of USD 4.67, marking a significant milestone for the microcap company in the Pharmaceuticals & Biotechnology sector. Over the past year, it has gained 21.7%, showcasing effective management despite being loss-making and navigating a challenging market landscape.

Read More
ADC Therapeutics SA Hits New 52-Week High of USD 4.31

ADC Therapeutics SA Hits New 52-Week High of USD 4.31

ADC Therapeutics SA achieved a new 52-week high of USD 4.31 on October 3, 2025, significantly up from its low of USD 1.05. With a market cap of USD 405 million, the company has a strong return on equity of 84.56% and a unique financial structure reflected in its debt-to-equity ratio.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
112.90%
EBIT Growth (5y)
11.20%
EBIT to Interest (avg)
-12.16
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.07
Sales to Capital Employed (avg)
-0.33
Tax Ratio
0.62%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
77.95%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-1.62
EV to EBIT
-5.11
EV to EBITDA
-5.24
EV to Capital Employed
40.12
EV to Sales
8.46
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-785.24%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 20 Schemes (8.95%)

Foreign Institutions

Held by 25 Foreign Institutions (8.21%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -18.26% vs 36.09% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -46.63% vs -25.73% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "18.80",
          "val2": "23.00",
          "chgp": "-18.26%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-30.20",
          "val2": "-27.70",
          "chgp": "-9.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "13.00",
          "val2": "12.20",
          "chgp": "6.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-13.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-56.60",
          "val2": "-38.60",
          "chgp": "-46.63%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,648.50%",
          "val2": "-1,235.80%",
          "chgp": "-41.27%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 1.72% vs -66.84% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 34.28% vs -52.83% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "70.80",
          "val2": "69.60",
          "chgp": "1.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-127.40",
          "val2": "-161.10",
          "chgp": "20.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "50.20",
          "val2": "46.30",
          "chgp": "8.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "11.50",
          "val2": "3.90",
          "chgp": "194.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-157.80",
          "val2": "-240.10",
          "chgp": "34.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,844.40%",
          "val2": "-2,363.20%",
          "chgp": "51.88%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
18.80
23.00
-18.26%
Operating Profit (PBDIT) excl Other Income
-30.20
-27.70
-9.03%
Interest
13.00
12.20
6.56%
Exceptional Items
-13.10
0.00
Consolidate Net Profit
-56.60
-38.60
-46.63%
Operating Profit Margin (Excl OI)
-1,648.50%
-1,235.80%
-41.27%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is -18.26% vs 36.09% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -46.63% vs -25.73% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
70.80
69.60
1.72%
Operating Profit (PBDIT) excl Other Income
-127.40
-161.10
20.92%
Interest
50.20
46.30
8.42%
Exceptional Items
11.50
3.90
194.87%
Consolidate Net Profit
-157.80
-240.10
34.28%
Operating Profit Margin (Excl OI)
-1,844.40%
-2,363.20%
51.88%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 1.72% vs -66.84% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 34.28% vs -52.83% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About ADC Therapeutics SA stock-summary
stock-summary
ADC Therapeutics SA
Pharmaceuticals & Biotechnology
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
Company Coordinates stock-summary
Company Details
Biopole, route de la Corniche 3B , EPALINGES None : 1066
stock-summary
Tel: 41 21 6530200
stock-summary
https://adctherapeutics.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."